# US 2026/0085077 A1 · Heterocyclic derivatives as janus kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085077 A1
- Document ID: US20260085077A1
- Status: Published application
- Kind: A1
- Application number: 19/109,331
- Filed: 2023-09-08
- Published: 2026-03-26
- Earliest claimed: 2022-09-09
- Assignees: Chiesi Farmaceutici S.p.A.
- Applicants: Chiesi Farmaceutici S.P.A.
- Inventors: Alessandro ACCETTA; Alberto CUZZOLIN; Fabio RANCATI; Andrea RIZZI; Ivaylo Jivkov ELENKOV; Milan MESIC; Ela RADOŠEVIC
- Web page: https://patentgrep.com/patent/US20260085077A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/538: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 471/04: Ortho-condensed systems
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory diseases including asthma, COPD and other respiratory diseases.

## Claims

### Claim at position 1

1: A compound of formula I
wherein:
R1 is a heteroaryl group selected from the group consisting of imidazo[1,2-b]pyridazin-3-yl, pyrazolo[1,5-a]pyrimidin-3-yl and 3-oxo-(3,4-dihydropyrazin-2-yl)amino;
R2 is a group of formula
that is a substituent group linked to the molecule scaffold,
wherein
V is a bond or is a divalent group selected from the group consisting of O, S, N(R6), C(O)N(R6), N(R6)C(O); N(R6)C(O)O; N(R6)S(O)2; and N(R6)C(O)N(R6);
Q is selected from the group consisting of H, (C1-C6)alkyl, (C1-C6)hydroxyalkyl, (C1-C6)alkoxy, —(CH2)mNR4R5, (C3-C8)cycloalkyl, (C3-C10)heterocycloalkyl; —S—(C3-C6)heterocycloalkyl, and —N(R6)—(C3-C6)heterocycloalkyl; wherein said (C3-C8)cycloalkyl and (C3-C10)heterocycloalkyl are further optionally substituted by one or more substituent selected from the group consisting of —OH, oxo, (C1-C10)alkyl, (C1-C6)alkoxy; halogen, (C1-C6)haloalkyl, alkanoyl, (C1-C6)hydroxyalkyl, (C1-C6)alkoxy(C1-C6)alkyl, —N(R6)(CH2)mC(O)NR4R5, —(CO)NR4R5, —(CH2)mNR4R5, (C3-C8)cycloalkyl(C1-C6)alkyl; (C3-C6)heterocycloalkyl(C1-C6)alkyl, (C3-C6)heterocycloalkyl and hydroxyl-(C3-C6)heterocycloalkyl;
R3 is a bicyclic moiety which is a substituent group linked to the scaffold graphically represented by
wherein the dashed line indicates a single or a double bond;
X is selected from the group consisting of N, S, and C;
Y is selected from the group consisting of Cand N;
Z is selected from the group consisting of C, N, and O;
K is a bond or selected from the group consisting of O, C, and S;
G is a bond or selected from the group consisting of C and O;
is the point of attachment of a substituent group to the rest of the molecule;
n and m are in each occurrence independently 0, 1, 2, 3 or 4;
R4 and R5 are each independently selected from the group consisting of
—H,
(C1-C6)alkyl,
(C1-C6)haloalkyl, and
(C3-C6)heterocycloalkyl;
R6 is in each occurrence independently selected from the group consisting of H, (C1-C6)alkyl and (C1-C6)hydroxyalkyl;
R7 is one or more group in each occurrence independently selected from the group consisting of —OH, oxo, (C1-C6)alkyl, halogen, (C1-C6)haloalkyl, (C1-C6)hydroxyalkyl, —(CH2)mNR4R5, (C1-C6)alkyl-S(O)2— and (C1-C6)alkyl-S(O)2N(R6)—; and
R8 is selected from the group consisting of (C1-C6)alkoxy and (C1-C6)haloalkoxy;
a single enantiomer, a diastereoisomer, a mixture thereof in any proportion,
or a pharmaceutically acceptable salt or solvate thereof.

### Claim at position 2 (depends on 1)

2: The compound, single enantiomer, diastereoisomer, mixture thereof, or pharmaceutically acceptable salt or solvate thereof, according to claim 1
wherein the bicyclic moiety R3
is selected from the group consisting of

### Claim at position 3 (depends on 2)

3: The compound, single enantiomer, diastereoisomer, mixture thereof, or pharmaceutically acceptable salt or solvate thereof, of according to claim 2
wherein the bicyclic moiety R3 is selected from the group consisting of J1-J13

### Claim at position 4 (depends on 3)

4: The compound, single enantiomer, diastereoisomer, mixture thereof, or pharmaceutically acceptable salt or solvate thereof, according to claim 3
wherein
R3 is J1 and R8 is methoxy;
the compound being thus represented by the formula Ia
wherein
R1 is pyrazolo[1,5-a]pyrimidin-3-yl or (3-oxo-3,4-dihydropyrazin-2-yl)amino;
V is a divalent group selected from the group consisting of C(O)N(R6) and N(R6)C(O)O;
Q is selected from the group consisting of (C1-C6)alkyl, (C1-C6)alkoxy, —(CH2)mNR4R5, (C3-C8)cycloalkyl and (C3-C12)heterocycloalkyl; wherein said (C3-C8)cycloalkyl and (C3-C12)heterocycloalkyl are further optionally substituted by one or more substituent selected from the group consisting of oxo, (C1-C10)alkyl, halogen, (C1-C6)hydroxyalkyl, —(CO)NR4R5; (C3-C8)cycloalkyl(C1-C6)alkyl; (C3-C6)heterocycloalkyl;
n and m are in each occurrence independently 0, 1, 2, 3 or 4;
R4 and R5 are in each occurrence independently selected from the group consisting of
—H,
(C1-C6)alkyl, and
(C1-C6)haloalkyl.

### Claim at position 5 (depends on 4)

5: The compound, single enantiomer, diastereoisomer, mixture thereof, or pharmaceutically acceptable salt or solvate thereof, according to claim 4 wherein
V is N(R6)C(O)O;
Q is selected from the group consisting of (C1-C6)alkyl, (C1-C6)alkoxy, —(CH2)mNR4R5, and (C3-C6)heterocycloalkyl being a group
wherein X1 is selected from the group consisting of CH2, O, S, NH, NCH3, (C═O) and S(═O)2.

### Claim at position 6 (depends on 4)

6: The compound, single enantiomer, diastereoisomer, mixture thereof, or pharmaceutically acceptable salt or solvate thereof, according to claim 4 wherein
V is C(O)N(R6),
Q is selected from the group consisting of —(CH2)mNR4R5, and (C3-C6)heterocycloalkyl being a group
wherein X1 is selected from the group consisting of CHR9, O, S, NH, NCH3, CF2, (C1-C6) alkoxy and (C1-C6)alkoxy(C1-C6)alkyl, wherein R9 is H or —(CO)NR4R5.

### Claim at position 7 (depends on 4)

7: The compound, single enantiomer, diastereoisomer, mixture thereof, or pharmaceutically acceptable salt or solvate thereof, according to claim 4 wherein
Q is (C3-C6)heterocycloalkyl, —S—(C3-C6)heterocycloalkyl or —N(R6)—(C3-C6)heterocycloalkyl selected from the group consisting of:

### Claim at position 8 (depends on 1)

8: The compound, single enantiomer, diastereoisomer, mixture thereof, or pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein the compound is selected from the group consisting of:
6-(difluoromethoxy)-7-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine,
1-(6-methoxy-2-(methylsulfonyl)isoindolin-5-yl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine,
8-methoxy-7-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-1,3,4,5-tetrahydro-2H-benzo[b]azepin-2-one,
7-methoxy-6-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-3,4-dihydroquinolin-2 (1H)-one,
7-methoxy-6-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-2,3-dihydroquinolin-4 (1H)-one,
6-methoxy-7-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-3,4-dihydro-2H-benzo[b][1,4]thiazine,
6-methoxy-7-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-2H-benzo[b][1,4]thiazin-3 (4H)-one,
6-methoxy-7-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-3,4-dihydro-2H-benzo[b][1,4]thiazine 1,1-dioxide,
7-methoxy-8-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine,
6-methoxy-5-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)indolin-2-one,
2,2-difluoro-6-methoxy-7-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-2H-benzo[b][1,4]oxazin-3 (4H)-one,
7-methoxy-3-methyl-6-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-3,4-dihydroquinazolin-2 (1H)-one,
1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-N-(1-((tetrahydro-2H-pyran-4-yl)methyl)azetidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
N-(3-(4,4-difluoropiperidin-1-yl)propyl)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-(2-oxo-1-oxa-8-azaspiro[4.5]decan-8-yl)ethyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
N-(3-(dimethylamino)propyl)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-N-(1-methylazetidin-3-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
(R)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-N-((4-methylmorpholin-2-yl)methyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
3-(2-oxomorpholino)propyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
2-(methyl(2-oxotetrahydrofuran-3-yl)amino)ethyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
(R)-1-(6-methoxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-N-((4-methylmorpholin-2-yl)methyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
(S)-1-(6-methoxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-N-((4-methylmorpholin-2-yl)methyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
N-(3-(dimethylamino)propyl)-1-(6-methoxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
N-(3-(dimethylamino)propyl)-1-(7-methoxy-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
N-(3-(dimethylamino)propyl)-1-(7-methoxy-1,2,3,4-tetrahydroquinolin-6-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
7-methoxy-6-(3-(methylamino)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-3,4-dihydroquinolin-2 (1H)-one,
2-(dimethylamino)ethyl (1-(7-methoxy-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
2-(dimethylamino)ethyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
2-morpholinoethyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
3-(4-methylpiperazin-1-yl)propyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
2-(piperidin-1-yl)ethyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
(R)-1-methylpyrrolidin-3-yl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
(S)-1-methylpyrrolidin-3-yl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
(4-(dimethylamino)tetrahydro-2H-pyran-4-yl)methyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
(R)-2-(3-methoxypyrrolidin-1-yl)ethyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
3-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]thiazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-1,1-dimethylurea,
6-methoxy-7-(3-((2-(4-methylpiperazin-1-yl)ethyl)amino)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-2H-benzo[b][1,4]thiazin-3 (4H)-one,
7-(3-((2-(dimethylamino)ethyl)amino)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-6-methoxy-2H-benzo[b][1,4]thiazin-3 (4H)-one,
1-(6-methoxybenzo[d]isothiazol-5-yl)-N-(2-morpholinoethyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-amine,
6-methoxy-7-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine,
1-(6-methoxyindolin-5-yl)-3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine,
7-methoxy-6-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)-1,2,3,4-tetrahydroquinoline,
N-(3-(dimethylamino)propyl)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(1-methylazetidin-3-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
(R)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-((4-methylmorpholin-2-yl)methyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-(4-methoxypiperidin-1-yl)ethyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-(4-(methoxymethyl)piperidin-1-yl)ethyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
N-(2-(7-oxa-2-azaspiro[3.5]nonan-2-yl)ethyl)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
N-(2-(2-oxa-6-azaspiro[3.5]nonan-6-yl)ethyl)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-((3aS,6aR)-1-oxotetrahydro-1H-furo[3,4-c]pyrrol-5 (3H)-yl)ethyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-(3-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)ethyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-(1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)ethyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
N-(2-(4-(dimethylcarbamoyl)piperidin-1-yl)ethyl)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
N1-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-N2,N2-dimethylethane-1,2-diamine,
1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-amine,
methyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
2-(dimethylamino)ethyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
2-morpholinoethyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
3-(4-methylpiperazin-1-yl)propyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
3-(dimethylamino)propyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
3-morpholinopropyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
2-(1,1-dioxidothiomorpholino)ethyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
2-(4-methylpiperazin-1-yl)ethyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
2-thiomorpholinoethyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
(S)-(4-methylmorpholin-2-yl)methyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
2-(piperidin-1-yl)ethyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
2-((2-oxotetrahydrofuran-3-yl)thio)ethyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
2-((2-oxotetrahydrofuran-3-yl)amino)ethyl (1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
2-(dimethylamino)ethyl (1-(7-methoxy-1,2,3,4-tetrahydroquinolin-6-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate,
1-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-(3-morpholinopropyl)urea,
6′-methoxy-5′-(3-methyl-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)spiro[cyclopropane-1,3′-indolin]-2′-one,
5-methoxy-6-(3-((2-morpholinoethyl)amino)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)benzo[d]oxazol-2 (3H)-one,
N-(3-(dimethylamino)propyl)-6-(imidazo[1,2-b]pyridazin-3-yl)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
3-((3-((2-(dimethylamino)ethyl)amino)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrazin-2 (1H)-one,
N-(3-(dimethylamino)propyl)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-((3-oxo-3,4-dihydropyrazin-2-yl)amino)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
N-(3-(4,4-difluoropiperidin-1-yl)propyl)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-((3-oxo-3,4-dihydropyrazin-2-yl)amino)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
N-(2-(2,2-dimethyl-6-oxomorpholino)ethyl)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
1-(6-(difluoromethoxy)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(3-(dimethylamino)propyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
N-(2-(4-carbamoylpiperidin-1-yl)ethyl)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
(R)—N-(2-(3-carbamoylpyrrolidin-1-yl)ethyl)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-(7-oxo-6-oxa-2-azaspiro[3.4]octan-2-yl)ethyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
N-(2-(2-oxa-6-azaspiro[3.4]octan-6-yl)ethyl)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-(2-methyl-6-oxomorpholino)ethyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
N-(1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-1-methylpiperidine-4-carboxamide,
N-(2-(4-(3-hydroxyoxetan-3-yl)piperidin-1-yl)ethyl)-1-(6-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide, and
2-((2-oxotetrahydrofuran-3-yl)thio)ethyl (1-(7-methoxy-1,2,3,4-tetrahydroquinolin-6-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)carbamate.

### Claim at position 9 (depends on 1)

9: A pharmaceutical composition comprising the compound, single enantiomer, diastereoisomer, mixture thereof, or pharmaceutically acceptable salt or solvate thereof, according to claim 1 in admixture with at least one pharmaceutically acceptable carrier or excipient.

### Claim at position 10 (depends on 9)

10: The pharmaceutical composition according to claim 9, which is formulated as inhalable powders, propellant-containing metering aerosols, or propellant-free inhalable formulations, to be administered by inhalation.

### Claim at position 11 (depends on 10)

11: A device comprising the pharmaceutical composition according to claim 10, which is a single- or multi-dose dry powder inhaler, a metered dose inhaler, or a soft mist nebulizer.

### Claim 12

(canceled)

### Claim at position 13 (depends on 9)

13: A method for treating a pulmonary disease selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), acute lung injury and acute respiratory distress syndrome (ARDS), the method comprising administering the pharmaceutical composition of claim 9 to a subject in need thereof.

### Claim at position 14 (depends on 1)

14: A composition comprising:
the compound, single enantiomer, diastereoisomer, mixture thereof, or pharmaceutically acceptable salt or solvate thereof, according to claim 1, and
one or more active ingredients selected from the group consisting of a beta2-agonist, an antimuscarinic agent, a corticosteroid, a mitogen-activated kinase (P38 MAP kinase) inhibitor, a PI3K inhibitors (phosphoinositide 3-kinase), a nuclear factor kappa-B kinase subunit beta inhibitor (IKK2), a Rho kinase inhibitor (ROCKi), a human neutrophil elastase (HNE) inhibitor, a phosphodiesterase 4 (PDE4) inhibitor, a leukotriene modulator, a non-steroidal anti-inflammatory agent (NSAIDs), and a mucus regulator.
